Career Enhancement Program
- Institution
- UNIV OF NORTH CAROLINA CHAPEL HILL, NC
- Principal investigator
- Melinda S. Yates
- Funding
- $251K
- Duration
- 2025–2030
Moonbase score
Still being scored
Abstract
ABSTRACT – CAREER ENHANCEMENT PROGRAM The Cancer Health Disparities SPORE in Endometrial Cancer Career Enhancement Program (CEP) supports research activities for oncology clinicians, oncology clinician scientists, and basic, translational, and clinical scientists with strong interest in cancer health disparities and endometrial cancer research. The SPORE leadership is committed to increasing the pool of endometrial cancer researchers. Each year the CEP will fund 2 CEP investigators from a total of $100,000 in SPORE and matched Institutional funds. We will recruit faculty with an existing endometrial cancer science focus; or have existing health disparities research expertise that is newly being applied to the endometrial cancer context to expand the field. The Cancer Health Disparities SPORE in Endometrial Cancer CEP will provide a rigorous mentorship program for all awardees and a broad ongoing evaluation of their progress. The SPORE and CEP additionally provide fiscal administration, biostatistics and bioinformatics input, biospecimens, genomics and pathology expertise; patient perspective and integration with community outreach activities; mentorship and critical analysis and constructive feedback on progress via CEP advisory board meetings.
LOADING MOONBASE SCORE
Questions for UNIV OF NORTH CAROLINA CHAPEL HILL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Univ of North Carolina Chapel HillNot yet scored
Project 3: Obesity-related Metabolic Reprogramming in Endometrial Cancer Disparities
Melinda S. Yates · $251K · 2025–2030
- NIH · Univ of North Carolina Chapel Hill65
Cortical circuits for the integration of parallel short-latency auditory pathways
Hiroyuki Kato · $469K · 2022–2027
- NIH · Univ of North Carolina Chapel Hill47
Study to establish safety, tolerability and feasibility of LM11A-31 as a neuroprotective agent in aging people living with HIV and neurocognitive impairment on antiretroviral therapy
Rick B Meeker · $638K · 2023–2029